Главная страница
Медицина
Финансы
Экономика
Биология
Ветеринария
Сельское хозяйство
Юриспруденция
Право
Языкознание
Языки
Логика
Философия
Религия
Этика
Политология
Социология
История
Информатика
Вычислительная техника
Физика
Математика
Промышленность
Энергетика
Искусство
Культура
Химия
Электротехника
Связь
Автоматика
Геология
Экология
Начальные классы
Строительство
образование
Механика
Воспитательная работа
Русский язык и литература
Дошкольное образование
Реферат
Урок
Отчет
Программа
Закон
Курсовая
Задача
Занятие
Решение
Лекция
Протокол

туберкулезччч. Президент Российского общества фтизиатровАссоциации фтизиатров


Скачать 415.2 Kb.
НазваниеПрезидент Российского общества фтизиатровАссоциации фтизиатров
Анкортуберкулезччч
Дата25.02.2022
Размер415.2 Kb.
Формат файлаdocx
Имя файлаTuberkulez u vzroslyh_2021.docx
ТипДокументы
#373663
страница39 из 51
1   ...   35   36   37   38   39   40   41   42   ...   51

Список литературы





    1. Фтизиатрия. Национальное руководство / под ред. М.И. Перельмана. - М. ГЭОТАР- Медна, 2007. - 512 с.

    2. Susceptibility testing of Mycobacteria, Nocardia, and other aerobic Actinomycetes; approved standard. NCCLS document M-24A. Clinical and Laboratory Standards Institute, Wayne, PA, Vol. 26, N 23, 2007

    3. Bifani PJ, Mathema B, Kurepina NE, Kreiswirth BN Global dissemination of the Mycobacterium tuberculosis W-Beijing family strains. Trends Microbiol. 2002;10:45–52 10.1016/S0966-842X(01)02277-6

    4. Munro SA et al. Patient adherence to tuberculosis treatment: a systematic review of the Beijing strain family in Russia. Journal of the American Medical Association, 2005. 293: 2726–2731.

    5. Vyazovaya A., Mokrousov I.,Zhuravlev V., Solovieva N., Otten T.,Vishnevsky B., Narvskaya O. Dominance of the Beijing genotype among XDR Mycobacterium tuberculosis strains in Russia/ International Journal of Mycobacteriology, v. 4, (2015), p. 84 – 85.

    6. World Health Organization. Tuberculosis handbook. Geneva: WHO, 1998.

    7. WHO/IUATLD Antituberculosis drug resistance in the world. Report No 3. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. Geneva: WHO, 2004

    8. The end TB strategy: global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva, World Health Organization, 2014 (http://www.who.int/tb/post2015_TBstrategy.pdf?ua=1, accessed 5 March 2015)

    9. NIAID Tuberculosis Working Group. NIAID research agenda. Multidrug-resistant and extensively drug-resistant tuberculosis. 2007. URL: http://www3.niaid.nih.gov/topics/tuberculosis/Research/PDF/MDRXDRTBresearchAgen da06-06-07.pdf.

    10. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis.

- 5th ed. Geneva: WHO, 2015.

    1. World Health Organization. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec 2006; No81 (45):430– 432.

    2. Sotgiu G., Ferrara G., Matteelli A. et al. Epidemiology and clinical management of XDR- TB: A systematic review by TBNET. Eur Respir J 2009; No33 (4):871–881.

    3. World Health Organization. Global tuberculosis report. 2019: WHO, 2019.

    4. ЦНИИОИЗ/ Центр мониторинга по туберкулеза/Аналитические обзоры/Ситуация по туберкулезу в 2018 года https://mednet.ru/images/materials/CMT/2018_god_tuberkulez_epidsituaciya.pdf.

    5. Lyon S, Rossman M. 2017. Pulmonary Tuberculosis. Microbiol Spectrum 5(1):TNMI7- 0032-2016. doi:10.1128/microbiolspec.TNMI7-0032-2016.

    6. Sreeramareddy CT, Qin ZZ, Satyanarayana S, Subbaraman R, Pai M. Delays in diagnosis and treatment of pulmonary tuberculosis in India: a systematic review. Int J Tuberc Lung Dis. 2014;18(3):255–66.

    7. Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health. 2008;8:15.

    8. Subbaraman R, Nathavitharana RR, Satyanarayana S, Pai M, Thomas BE,Chadha VK, Rade K, Swaminathan S, Mayer KH. The Tuberculosis Cascade of Care in India's Public Sector: A Systematic Review and Meta-analysis. PloS Med. 2016 Oct 25;13(10):e1002149. doi: 10.1371/journal.pmed.1002149.

    9. Singh P1, Saket VK2, Kachhi R. Diagnosis of TB: From conventional to modern molecular protocols. Front Biosci (Elite Ed). 2019 Jan 1;11:38-60.

    10. Kunkel A, Abel Zur Wiesch P, Nathavitharana RR, Marx FM, Jenkins HE, Cohen T .Smear positivity in paediatric and adult tuberculosis: systematic review and meta-analysis. BMC Infect Dis.2016 Jun 13;16:282. doi: 10.1186/s12879-016-1617-9.

    11. Ho J, Marks GB, Fox GJ. The impact of sputum quality on tuberculosis diagnosis: a systematic review. Int J Tuberc Lung Dis. 2015 May; 19(5):537-44. doi: 10.5588/ijtld.14.0798.

    12. Davis JL, Cattamanchi A, Cuevas LE et al. Diagnostic accuracy of same-day microscopy versus standard microscopy for pulmonary tuberculosis: a systematic review and meta- analysis. Lancet Infectious Diseases, 2013, 13:147–154.

    13. IUATLD . Sputum examination for tuberculosis by direct microscopy in low income Countries: technical guide. 5. Paris: IUATLD; 2000.

    14. Lu C, Liu Q, Sarma A, Fitzpatrick C, Falzon D, Mitnick CD. A systematic review of reported cost for smear and culture tests during multidrug-resistant tuberculosis treatment. PLoS One. 2013;8(2):e56074. doi: 10.1371/journal.pone.0056074.

    15. Bonnett LJ, Davies GR Quality of outcome reporting in phase II studies in pulmonary tuberculosis. Trials. 2015 Nov 14;16:518. doi: 10.1186/s13063-015-1050-1.

    16. Hepple P, Ford N, Mc Nerney R Microscopy compared to culture for the diagnosis of tuberculosis in induced sputum samples: a systematic review. Int J Tuberc Lung Dis. 2012 May;16(5):579-88. doi: 10.5588/ijtld.11.0617

    17. Migliori G.B., Zellweger J.P., Abubakar I. et al. European Union standards for tuberculosis care. Eur Respir J 2012; No39 (4):807–819. URL: http://dx.doi.org/10.1183/09031936.00203811

    18. Bauer M, Leavens A, Schwartzman K. A systematic review and meta-analysis of the impact of tuberculosis on health-related quality of life. Quality of Life Research 2013;22(8):2213–2235

    19. Bemer P., Palicova F., Rüsch-Gerdes S. et al. Multicenter evaluation of fully automated BACTEC mycobacteria growth indicator tube 960 system for susceptibility testing of mycobacterium tuberculosis. J Clin Microbiol 2002; No 40 (1):150-154.

    20. Lin S. Y., Desmond E., Bonato D. et al. Multicenter evaluation of Bactec MGIT 960 system for second-line drug susceptibility testing of mycobacterium tuberculosis complex. J Clin Microbiol 2009; No47 (11):3630–3634.

    21. Pfyffer G. E., Bonato D.A.. Ebrahimzadeh A. et al. Multicenter laboratory validation of susceptibility testing of mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. J Clin Microbiol 1999; No37 (10):3179–3186.

    22. Rusch-Gerdes S., Pfyffer G.E., Casal M. et al. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006; No44 (3):688-692.

    23. Siddiqi S. H., Rüsch-Gerdes S. MGIT procedure manual. For BACTEC MGIT 960 TB system (Also applicable for Manual MGIT). Mycobacteria growth indicator tube (MGIT) culture and drug susceptibility demonstration projects. Foundation for innovative new diagnostics, 2006.

    24. Denkinger CM, Schumacher SG, Boehme CC et al. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. European Respiratory Journal, 2014, doi:10.1183/09031936.00007814

    25. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug- resistant tuberculosis: a meta-analysis. European Respiratory Journal, 2008, 32:1165–1174

    26. Van Rie A, Page-Shipp L, Scott L, Sanne I, Stevens W. Xpert(R) MTB/RIF for point-of- care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Review of Molecular Diagnostics 2010. Oct;10(7):937-46

    27. Morgan M, Kalantri S, Flores L, Pai M. A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. BMC Infectious Diseases 2005; 5: 62-70

    28. Boehme C.C., Nicol M.P., Nabeta P. et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; No377 (9776): 1495–1505

    29. Lange C., Abubakar I., Alffenaar J.W. et al. Management of patients with multidrug- resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014; No44 (1):23–63.

    30. Rapid diagnostics of tuberculosis and its resistances. Nehren: Germany: Hain lifescience GmbH, 2015. http://www.hain- lifescience.de/uploadfiles/file/produkte/mikrobiologie/mykobakterien/tb_eng.pdf.

    31. Hillery N., Groessl E.J., Trollip A. et al. The global consortium for drug-resistant tuberculosis diagnostics (GCDD): design of a multi-site, head-to-head study of three rapid tests to detect extensively drug-resistant tuberculosis. Trials 2014; No15: 434 - 434.

    32. Lienhardt C et al. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Current Opinion in Pulmonary Medicine, 2010, 16(3):186–193..

    33. Falzon D., Jaramillo E., Schünemann H.J. et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; No38 (3):516–528.

    34. Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC. 2006. International standards for tuberculosis care. Lancet Infect. Dis. 6:710–725Wikman-Jorgensen P, Llenas-García J, Hobbins M, Ehmer J, Abellana R , Gonçalves AQ, Pérez-Porcuna TM, Ascaso C. Microscopic observation drug susceptibility assay for the diagnosis of TB and MDR-TB in HIV-infected patients: a systematic review and meta-analysis. Eur Respir J. 2014 Oct;44(4):973-84. doi: 10.1183/09031936.00079614.

    35. Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, Cambau E, Aubry A. A systematic review of gyrase mutations associated with fluoroquinolone- resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J

Antimicrob Chemother. 2012 Apr;67(4):819-31. doi: 10.1093/jac/dkr566. Epub 2012 Jan 25.

    1. Simultaneous drug resistance detection and genotyping of Mycobacterium tuberculosis using a low-density hydrogel microarray. J Antimicrob Chemother. 2016 Jun;71(6):1520- 31. doi: 10.1093/jac/dkw015. Epub 2016 Feb 29

    2. Chang KC, Yew WW, Chan RC. Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother. 2010; 65:1551–61.

    3. Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM et al. Population- based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis. 2016;16(10):1185–92

    4. Avalos E, Catanzaro D,
      1   ...   35   36   37   38   39   40   41   42   ...   51

написать администратору сайта